Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):859–863. doi: 10.1128/aac.37.4.859

2-substituted quinoline alkaloids as potential antileishmanial drugs.

A Fournet 1, A A Barrios 1, V Muñoz 1, R Hocquemiller 1, A Cavé 1, J Bruneton 1
PMCID: PMC187784  PMID: 8494383

Abstract

Ten 2-substituted quinoline alkaloids isolated from a plant used for treatment of New World cutaneous leishmaniasis have antileishmanial in vitro activities against the extracellular forms of Leishmania spp. BALB/c mice infected with Leishmania amazonensis PH8 or H-142 or Leishmania venezuelensis were treated 1 day after the parasitic infection with a quinoline alkaloid (100 mg/kg of body weight per day) or with reference drug N-methylglucamine antimonate (Glucantime) (56 mg of pentavalent antimony [Sbv] per kg per day) for 14 days. Lesion development was the criterium used to assess disease severity. Two three-carbon chain quinolines [2-n-propylquinoline and 2-(1',2'-trans-epoxypropyl)quinoline (chimanine D)] were more potent than N-methylglucamine antimonate against L. amazonensis PH8, and five quinoline alkaloids [2-(3,4-methylenedioxyphenylethyl)quinoline, cusparine, 2-(3,4-dimethoxyphenylethyl)quinoline, 2-(E)-prop-1'-enylquinoline (chimanine B), and skimmianine] were as effective as the reference drug. Single treatment near the site of infection, 14 days after infection with L. amazonensis, with 2-n-propylquinoline or chimanine B reduced the severity of lesions but less notably than N-methylglucamine antimonate. 2-n-Propylquinoline exhibited significant activity against the virulent strain L. venezuelensis. The active products did not show any apparent toxicities during the experiment. This study is, to our knowledge, the first to show the activity of 2-substituted quinoline alkaloids for experimental treatment of New World cutaneous leishmaniasis. Further investigations of these compounds might yet prove helpful for the development of new antileishmanial drugs.

Full text

PDF
859

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avila J. L., Rojas T., Monzón H., Convit J. Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice. Am J Trop Med Hyg. 1990 Aug;43(2):139–145. doi: 10.4269/ajtmh.1990.43.139. [DOI] [PubMed] [Google Scholar]
  2. Bartlett M. S., Queener S. F., Tidwell R. R., Milhous W. K., Berman J. D., Ellis W. Y., Smith J. W. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother. 1991 Feb;35(2):277–282. doi: 10.1128/aac.35.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berman J. D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis. 1988 May-Jun;10(3):560–586. doi: 10.1093/clinids/10.3.560. [DOI] [PubMed] [Google Scholar]
  4. Bonfante-Garrido R. New observations on Leishmania mexicana venezuelensis. Trans R Soc Trop Med Hyg. 1983;77(5):740–740. doi: 10.1016/0035-9203(83)90221-3. [DOI] [PubMed] [Google Scholar]
  5. Coleman R. E., Edman J. D., Semprevivo L. H. The effect of pentostam and cimetidine on the development of leishmaniasis (Leishmania mexicana amazonensis) and concomitant malaria (Plasmodium yoelii). Ann Trop Med Parasitol. 1989 Aug;83(4):339–344. doi: 10.1080/00034983.1989.11812354. [DOI] [PubMed] [Google Scholar]
  6. Hanham C. A., Shaw J. J., Lainson R., McMahon-Pratt D. Production of a specific monoclonal antibody for the identification of Leishmania (Leishmania) venezuelensis. Am J Trop Med Hyg. 1990 May;42(5):453–459. doi: 10.4269/ajtmh.1990.42.453. [DOI] [PubMed] [Google Scholar]
  7. Hanson W. L., Chapman W. L., Jr, Kinnamon K. E. Testing of drugs for antileishmanial activity in golden hamsters infected with Leishmania donovani. Int J Parasitol. 1977 Dec;7(6):443–447. doi: 10.1016/0020-7519(77)90004-2. [DOI] [PubMed] [Google Scholar]
  8. Kinnamon K. E., Steck E. A., Loizeaux P. S., Hanson W. L., Chapman W. L., Jr, Waits V. B. The antileishmanial activity of lepidines. Am J Trop Med Hyg. 1978 Jul;27(4):751–757. doi: 10.4269/ajtmh.1978.27.751. [DOI] [PubMed] [Google Scholar]
  9. Peters W., Trotter E. R., Robinson B. L. The experimental chemotherapy of leishmaniasis, VII. Drug responses of L. major and L. mexicana amazonensis, with an analysis of promising chemical leads to new antileishmanial agents. Ann Trop Med Parasitol. 1980 Jun;74(3):321–335. [PubMed] [Google Scholar]
  10. Saenz R. E., Paz H., Berman J. D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990 Aug;89(2):147–155. doi: 10.1016/0002-9343(90)90292-l. [DOI] [PubMed] [Google Scholar]
  11. Trotter E. R., Peters W., Robinson B. L. The experimental chemotherapy of leishmaniasis, VI. The development of rodent models for cutaneous infection with L. major and L. mexicana amazonensis. Ann Trop Med Parasitol. 1980 Jun;74(3):299–319. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES